AZN PE Ratio & Valuation,Is AZN Overvalued

AZN Relative Valuation

AZN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AZN is overvalued; if below, it's undervalued.

Historical Valuation

AstraZeneca PLC (AZN) is now in the Fair zone, suggesting that its current forward PE ratio of 18.07 is considered Fairly compared with the five-year average of 17.10. The fair price of AstraZeneca PLC (AZN) is between 83.09 to 114.38 according to relative valuation methord.

Relative Value

Fair Zone

83.09-114.38

Current Price：93.55

Fair

18.07

14.29

EV/EBITDA

AstraZeneca PLC. (AZN) has a current EV/EBITDA of 14.29. The 5-year average EV/EBITDA is 13.88. The thresholds are as follows: Strongly Undervalued below 11.41, Undervalued between 11.41 and 12.65, Fairly Valued between 15.12 and 12.65, Overvalued between 15.12 and 16.36, and Strongly Overvalued above 16.36. The current Forward EV/EBITDA of 14.29 falls within the Historic Trend Line -Fairly Valued range.

15.02

EV/EBIT

AstraZeneca PLC. (AZN) has a current EV/EBIT of 15.02. The 5-year average EV/EBIT is 14.62. The thresholds are as follows: Strongly Undervalued below 12.22, Undervalued between 12.22 and 13.42, Fairly Valued between 15.82 and 13.42, Overvalued between 15.82 and 17.02, and Strongly Overvalued above 17.02. The current Forward EV/EBIT of 15.02 falls within the Historic Trend Line -Fairly Valued range.

4.62

AstraZeneca PLC. (AZN) has a current PS of 4.62. The 5-year average PS is 4.22. The thresholds are as follows: Strongly Undervalued below 3.45, Undervalued between 3.45 and 3.83, Fairly Valued between 4.61 and 3.83, Overvalued between 4.61 and 4.99, and Strongly Overvalued above 4.99. The current Forward PS of 4.62 falls within the Overvalued range.

17.46

P/OCF

AstraZeneca PLC. (AZN) has a current P/OCF of 17.46. The 5-year average P/OCF is 18.07. The thresholds are as follows: Strongly Undervalued below 14.13, Undervalued between 14.13 and 16.10, Fairly Valued between 20.04 and 16.10, Overvalued between 20.04 and 22.01, and Strongly Overvalued above 22.01. The current Forward P/OCF of 17.46 falls within the Historic Trend Line -Fairly Valued range.

25.29

P/FCF

AstraZeneca PLC. (AZN) has a current P/FCF of 25.29. The 5-year average P/FCF is 24.69. The thresholds are as follows: Strongly Undervalued below 17.96, Undervalued between 17.96 and 21.33, Fairly Valued between 28.05 and 21.33, Overvalued between 28.05 and 31.42, and Strongly Overvalued above 31.42. The current Forward P/FCF of 25.29 falls within the Historic Trend Line -Fairly Valued range.

AstraZeneca PLC (AZN) has a current Price-to-Book (P/B) ratio of 6.18. Compared to its 3-year average P/B ratio of 5.44 , the current P/B ratio is approximately 13.68% higher. Relative to its 5-year average P/B ratio of 5.95, the current P/B ratio is about 3.95% higher. AstraZeneca PLC (AZN) has a Forward Free Cash Flow (FCF) yield of approximately 4.46%. Compared to its 3-year average FCF yield of 4.32%, the current FCF yield is approximately 3.33% lower. Relative to its 5-year average FCF yield of 3.89% , the current FCF yield is about 14.82% lower.

6.18

P/B

Median3y

5.44

Median5y

5.95

4.46

FCF Yield

Median3y

4.32

Median5y

3.89

Competitors Valuation Multiple

The average P/S ratio for AZN's competitors is 4.32, providing a benchmark for relative valuation. AstraZeneca PLC Corp (AZN) exhibits a P/S ratio of 4.62, which is 6.8% above the industry average. Given its robust revenue growth of 11.99%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of AZN increased by 34.48% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 10.56 to 16.69.

The secondary factor is the Revenue Growth, contributed 11.99%to the performance.

Overall, the performance of AZN in the past 1 year is driven by Margin Expansion. Which is more sustainable.

11.99%

13.57B → 15.19B

Revenue Growth

58.05%

10.56 → 16.69

Margin Expansion

-35.56%

47.16 → 30.39

P/E Change

34.48%

70.76 → 95.16

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is AstraZeneca PLC (AZN) currently overvalued or undervalued?

What is AstraZeneca PLC (AZN) fair value?

AZN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of AstraZeneca PLC (AZN) is between 83.09 to 114.38 according to relative valuation methord.

How does AZN's valuation metrics compare to the industry average?

The average P/S ratio for AZN's competitors is 4.32, providing a benchmark for relative valuation. AstraZeneca PLC Corp (AZN) exhibits a P/S ratio of 4.62, which is 6.80% above the industry average. Given its robust revenue growth of 11.99%, this premium appears unsustainable.

What is the current P/B ratio for AstraZeneca PLC (AZN) as of Jan 09 2026?

As of Jan 09 2026, AstraZeneca PLC (AZN) has a P/B ratio of 6.18. This indicates that the market values AZN at 6.18 times its book value.

What is the current FCF Yield for AstraZeneca PLC (AZN) as of Jan 09 2026?

As of Jan 09 2026, AstraZeneca PLC (AZN) has a FCF Yield of 4.46%. This means that for every dollar of AstraZeneca PLC’s market capitalization, the company generates 4.46 cents in free cash flow.

What is the current Forward P/E ratio for AstraZeneca PLC (AZN) as of Jan 09 2026?

As of Jan 09 2026, AstraZeneca PLC (AZN) has a Forward P/E ratio of 18.07. This means the market is willing to pay $18.07 for every dollar of AstraZeneca PLC’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for AstraZeneca PLC (AZN) as of Jan 09 2026?

As of Jan 09 2026, AstraZeneca PLC (AZN) has a Forward P/S ratio of 4.62. This means the market is valuing AZN at $4.62 for every dollar of expected revenue over the next 12 months.

AZN Valuation